Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Malmedy – page 45

922 clinical trials in Malmedy, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Malmedy at a glance
922
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

922 trials in Malmedy

Open in trial search

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MK-3508 in Healthy Participants for RSV Infection

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:MK-3508
  • Sponsor:Merck Sharp & Dohme LLC

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Study on the Safety and Tolerability of WVE-006 for Patients with Alpha-1 Antitrypsin Deficiency (AATD) Pi*ZZ

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:WVE-006
  • Sponsor:Wave Life Sciences Ireland Limited

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Novartis Pharma AG

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Bronchiectasis

Not recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD0292
  • Sponsor:AstraZeneca AB

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Malmedy

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on human Papillomavirus (HPV) infections, specifically targeting high-risk oncogenic strains that affect the genital area. The research aims to evaluate new therapeutic approaches for viral clearance.

  • Viral Infection Management
  • Therapeutic Efficacy Assessment
  • Preventive Medicine

This placebo-controlled study represents an important step in developing targeted treatments for persistent viral infections that could have long-term health implications.

02 Women's Health

Innovative research exploring treatments for gynecological viral conditions, with a focus on evaluating new therapeutic compounds against specific viral strains. The study emphasizes the importance of addressing persistent infections.

  • Reproductive Health
  • Infection Control
  • Preventive Care

This research initiative demonstrates the ongoing commitment to advancing treatment options in women's health and infection management.

03 Preventive Medicine

Advanced clinical research evaluating novel approaches to viral infection clearance, utilizing controlled trial methodologies to assess treatment effectiveness over an extended period.

  • Long-term Monitoring
  • Treatment Innovation
  • Clinical Assessment

The study's design reflects current best practices in clinical research, incorporating double-blind methodology to ensure reliable results.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.